A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants
Mayo Clinic
24 participants
Mar 11, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Eligibility
Inclusion Criteria5
- Males or non-pregnant females
- Age 18-80.
- Participants must be in good health based on medical history (ASA Class 3 or below)
- Participants must be willing and able to provide informed consent
- Receiving an endoscopic ultrasound for a non-pancreatic indication
Exclusion Criteria9
- History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).
- History of inflammatory bowel disease
- History of vagotomy.
- History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II)
- History of liver disease
- Pregnant women or nursing mothers
- Regular use of anticholinergics
- > 2 drinks of alcohol daily
- Smokers (cigarette)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07285863